Background: The human immunodeficiency virus (HIV) is a viral infection that destroys the 10 human immune system resulting in acquired immunodeficiency syndrome (AIDS). The Zambia 11 HIV prevalence rate is among the highest in the sub-Saharan Africa. With no HIV vaccine and 12 cure for HIV/AIDS, the antiretroviral (ARV) therapy that slows the spread of the virus remains 13 the only option. The administration of ARV has challenges of Transmitted Drug Resistance 14 Mutation strains (TDRMs) in the treatment of HIV naïve patients. To address these challenges, 15 we propose use of transition probabilities when prescribing a switch from first-line to second-16 line or to third-line regimen on ARV drugs combination.
Results: The estimates converge to the fitted model as demonstrated by the history and density
Construction of a three stage Beta-Binomial Hierarchical model 147 Let data (i =1,2,…n) be independent and identically distributed, drawn from a Binomial 
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The use of the hyper prior provides more information leading to more accurate opinions 170 on the behaviour of a parameter. 
(4) 174 Thus, ( , , | ) ∝ ( | ) ( | ) ( | ) ( ).
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Consider the probability that a patient switch from the first baseline treatment to be , 176 probability of treatment failure for combination i, which is the quantity of interest of the 177 analysis. The complement of this probability is the kernel probability of a patient remaining on 178 the first base regimen. We obtain a full probability model by combining the prior Beta (a, b), 179 the likelihood distribution ( | , ) and the hyper prior. Thus,
Hence, for each
, and | ~( + , + − ).
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The parameter ′ ,'s has a Beta (a, b) distribution assuming the ,'s to be independently and 
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• Convergence: It is essential to know how quickly the distribution of ( )
Results

214
The first baseline regimen results 215 We checked the convergence of the fitted model using plots and the deviance information The density plots of theta for the first baseline regimen is consistent with the summary 238 statistics. All parameters converged according to the auto-correlation statistic or plots and cross-239 correlation plots. The estimated values from the posterior distributions were used to produce 240 the probability transition matrix for each ARV therapy combination. Model checking for the second baseline 331 We compare the Bayesian model of the second baseline regimen on ARV combination, using The elements of the P matrix were computed to provide the transition probability 371 matrices for the first baseline regimen given in figure 5 . higher than that of moving to another state. The probability deceases as the chain state moves 376 from state 1 to 2, and 2 to 3. In all the states, there is no recorded direct move from state 1 to recorded moves were from states 1 to 2 and 2 to 3, with the rest remaining in the same state 379 with high probabilities. 
